Sign In
Buy NTRA
$318.35
-3.75 (-1.16%)
At Close: Aug 10, 2026
Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar?
09:06am, Thursday, 25'th Jun 2026
Natera (NTRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
07:00am, Thursday, 25'th Jun 2026
AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage
Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer
02:14pm, Wednesday, 24'th Jun 2026
Natera Inc. (NASDAQ:NTRA) said Japan's Ministry of Health, Labour and Welfare approved its Signatera molecular residual disease (MRD) test for patients with colorectal cancer in the adjuvant setting,
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
05:00am, Wednesday, 24'th Jun 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received regulatory approval from Japan's Pharm
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
03:00am, Wednesday, 24'th Jun 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received regulatory approval from Japan's Pharm
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
03:26pm, Tuesday, 23'rd Jun 2026
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
06:00am, Tuesday, 23'rd Jun 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has upda
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
06:00am, Thursday, 18'th Jun 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced its robust scientific presence at the upcoming American Transplant
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
08:22pm, Friday, 12'th Jun 2026
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC
12:52pm, Monday, 08'th Jun 2026
Natera teams with CytoDyn to track ctDNA in CLOVER Phase 2, using Signatera to map leronlimab response in metastatic colorectal cancer.
AUSTIN, Texas & VANCOUVER, Wash.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn”), a clinical-stag
Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)
03:36pm, Wednesday, 03'rd Jun 2026
Most investors' portfolios hold at least a couple of the market's biggest companies, just because these names are best-known to most investors. These crowded trades in already-massive companies, howev
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
08:00am, Wednesday, 03'rd Jun 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to t
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial
02:12pm, Monday, 01'st Jun 2026
Natera teams with Diakonos to use Signatera MRD testing in a refractory melanoma immunotherapy trial, tracking ctDNA to gauge response.
Why Natera Is My Favorite Stock Idea for the Rest of 2026
10:26am, Friday, 29'th May 2026
It's hard to pick just one favorite stock idea for the rest of the year. It's been a blistering-hot 2026, as the AI revolution keeps rolling ahead.
